Median Technologies unveils half-year results and strategic advances

On July 18, 2024, Median Technologies announced a record order backlog of €71.7 million as of June 30, 2024. The first major deals were signed for iCRO in Japan and South Korea. China, after the impact of Covid-19, is showing signs of recovery with an acceleration in orders in the first half of 2024.

The turnover for the first half of 2024 stands at 10.9 million euros, compared to 11.4 million euros for the same period in 2023. Median has been selected as a preferred supplier by two of the three largest global pharmaceutical laboratories.

Final results from the eyonis™ LCS verification study are promising, increasing confidence for the Standalone pivotal study results, expected in August. At the end of June 2024, the cash position reached 16 million euros, ensuring the financing of operations until the second quarter of 2025.